Nishizaki et al. found that the anticancer drug HUHS1015 can activate Caspase-4 and its downstream pathway as well as inhibit cell proliferation in prostate cancer cell lines, including DU145, LNCap and PC-3 [31]. Here, CASP4 is linked to prostate cancer.